10.1038/cddis.2016.121 [Google Scholar] Jaul E, Barron J (2017) Age-related diseases and clinical and public health implications for the 85 years old and over population
Kise S, Morita S, Sakaki T, Kimura H, Kinuya S, Yasuda K
Triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a Phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
This DMF-upregulated DNA hydroxymethylation affects CBS locus chromatin structure modifications and upregulates gene expression
Consistent Dosing: Standardised formulation aids in accurate dosing, allowing for reliable assessment across various experimental settings
Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-experienced patients with type 2 diabetes mellitus: a preference study in Germany and the United Kingdom